

57th ASH Annual Meeting and Exposition (December 5-8, 2015)

[Print](#)

- Saturday, 07:30 AM
December 5, 2015 2 (WF2)* Tangerine
Bortezomib, Lenalidomide and Dexamethasone Vs. Lenalidomide and Dexamethasone in Patients (Pts) with Previously Untreated Multiple Myeloma without an Intent for Immediate Autologous Stem Cell Transplant (ASCT): Results of the Randomized Phase III Trial SWOG S0777 -25
Brian Durie, MD, Antje Hoering, PhD, S. Vincent Rajkumar, MD, Muneer H. Abidi, MD, Joshua Epstein, DSc, Stephen P. Kahanic, MD, Mohan C. Thakuri, MD, Frederic J Reu, Christopher M. Reynolds, MD, Rachael Sexton, MS, Robert Z. Orlowski, Ph.D., M.D., Bart Barlogie, MD, PhD, Angela Dispenzieri, MD
- 07:30 AM -
09:00 AM*
653. Myeloma: Therapy, excluding Transplantation: Advances in Newly Diagnosed and Relapsed Myeloma
Thierry Facon, Michele Cavo, Thierry Facon, Michele Cavo, Nikhil C. Munshi, MD, Meletios A. Dimopoulos
- 07:45 AM*
Randomized Phase 2 Study of the All-Oral Combination of Investigational Proteasome Inhibitor (PI) Ixazomib Plus Cyclophosphamide and Low-Dose Dexamethasone (ICd) in Patients (Pts) with Newly Diagnosed Multiple Myeloma (NDMM) Who Are Transplant-Ineligible (NCT02046070) -26
Meletios A. Dimopoulos, Sebastian Grosicki, MD, PhD, Wieslaw W Jedrzejczak, MD PhD, Hareth Nahi, Astrid Gruber, MD, PhD, Markus Hansson, Catriona Byrne, RN, Richard Labotka, MD, MS, Ai-Min Hui, MD, PhD, Zhaoyang Teng, PhD, Norbert Grzasko, MD, PhD
- 08:00 AM*
Bortezomib Induction and Maintenance in Patients with Newly Diagnosed Multiple Myeloma: Long-Term Follow-up of the HOVON-65/GMMG-HD4 Trial -27
Pieter Sonneveld, MD, PhD, Hans-Juergen Salwender, MD, Bronno Van Der Holt, PhD, Laila el Jarari, Uta Bertsch, MD, Igor W. Blau, MD, Sonja Zweegman, Katja C. Weisel, Edo Vellenga, MD PhD, Michael Pfreundschuh, Annemiek Broijl, MD, PhD, Christof Scheid, MD PhD, Shulamiet Wittebol, MD, Gerard M.J. Bos, MD, PhD, Marjan Stevens-Kroef, Anna Jauch, Anna Potamianou, MD, PhD, Dirk Hose, MD, Reinier Raymakers, MD, PhD, Marinus Schaafsme, Marie Jose Kersten, MD, PhD, Marinus van Marwijk Kooy, Ulrich Duehrsen, Prof. Dr. med., Hans Walter Lindemann, MD, Peter Brossart, MD, Pierre Wijermans, Henk M. Lokhorst, Hartmut Goldschmidt, MD
- 08:15 AM*
Eloquent-2 Update: A Phase 3, Randomized, Open-Label Study of Elotuzumab in Combination with Lenalidomide/Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma - 3-Year Safety and Efficacy Follow-up -28
Meletios A. Dimopoulos, Sagar Lonial, MD, Darrell White, MD, Philippe

Moreau, MD, Antonio Palumbo, MD, Jesus San Miguel, MD PhD, Ofer Shpilberg, MD, MPH, Kenneth C. Anderson, M.D, Sebastian Grosicki, MD, PhD, Ivan Spicka, MD, PhD, Adam Walter-Croneck, Hila Magen-Nativ, Maria-Victoria Mateos, Andrew Belch, Donna Reece, Meral Beksac, MD, Eric Bleickhardt, Valerie Poulart, Jessica Katz, Anil K. Singhal, Paul G. Richardson, MD

08:30 AM Clinical Efficacy of Daratumumab Monotherapy in Patients with Heavily Pretreated Relapsed or Refractory Multiple Myeloma -29
Saad Usmani, Brendan Weiss, Nizar J Bahlis, MD, Andrew Belch, Sagar Lonial, MD, Henk Lokhorst, Peter M. Voorhees, MD, Paul G. Richardson, MD, A Kate Sasser, Amy Axel, Huaibao Feng, Clarissa Uhlar, Jianping Wang, Imran Khan, Tahamtan Ahmadi, Hareth Nahi

08:45 AM Efficacy and Safety of Carfilzomib and Dexamethasone Vs Bortezomib and Dexamethasone in Patients with Relapsed Multiple Myeloma Based on Cytogenetic Risk Status: Subgroup Analysis from the Phase 3 Study Endeavor (NCT01568866) -30
Wee-Joo Chng, Hartmut Goldschmidt, Meletios A. Dimopoulos, Philippe Moreau, MD, Douglas Joshua, Antonio Palumbo, Thierry Facon, Heinz Ludwig, Ludek Pour, MD, Ruben Niesvizky, Albert Oriol, MD, Laura Rosinol, Aleksandr Suvorov, Gianluca Gaidano, Tomas Pika, Katja Weisel, Vesselina Goranova-Marinova, Heidi H. Gillenwater, Nehal Mohamed, Shibao Feng, Roman Hájek

02:00 PM
W414AB CAR-Engineered T Cells Specific for the Elotuzumab Target SLAMF7 Eliminate Primary Myeloma Cells and Confer Selective Fratricide of SLAMF7+ Normal Lymphocyte Subsets -115
Sophia Danhof, MD, Tea Gogishvili, PhD, Silvia Koch, Martin Schreder, MD, Stefan Knop, Hermann Einsele, Michael Hudecek, MD

02:30 PM Target Expression, Preclinical Activity and Mechanism of Action of EM801: A Novel First-in-Class Bcma T-Cell Bispecific Antibody for the Treatment of Multiple Myeloma -117
Anja Seckinger, MD, Jose Antonio Delgado, Laura Moreno, Brigitte Neuber, PhD, Anna Grab, PhD, Susanne Lipp, MS, Juana Merino, MD PhD, Minh Diem Vu, PhD, Klaus Strein, MD, PhD, Felipe Prosper, MD PhD, Michael Hundemer, MD, Jesus San Miguel, MD PhD, Dirk Hose, MD, Bruno Paiva, PhD

05:30 PM -
07:30 PM
Hall A Tuning T Cell Affinity Improves Efficacy and Safety of Anti-CD38 × Anti-CD3 Bispecific Antibodies in Monkeys - a Potential Therapy for Multiple Myeloma -1798
Gregory L. Moore, PhD, Sung-Hyung Lee, PhD, Suzanne Schubert, PhD, Yvonne Miranda, MS, Rumana Rashid, PhD, Erik Pong, BS, Sheryl Phung, MS, Emily W. Chan, BS, Hsing Chen, MS, Nancy Endo, BS, Maria C. Ardila, BS, Matthew J. Bernett, PhD, Seung Chu, PhD, Irene W.L. Leung, PhD, Umesh Muchhal, PhD, Christine Bonzon, PhD, David E Szymkowski, PhD, John Desjarlais, PhD, Paul A. Foster, MD

Sunday, **06:00 PM -**
08:00 PM Immunomodulatory Effects and Adaptive Immune Response to Daratumumab in Multiple Myeloma -3037

*December Hall A
6, 2015*

Jakub Krejcik, Tineke Casneuf, Inger Nijhof, Bie Verbist, Jaime Bald, Torben Plesner, MD, Kevin Liu, Niels W.C.J. van de Donk, Brendan Weiss, Tahamtan Ahmadi, Henk M. Lokhorst, Tuna Mutis, A. Kate Sasser

*Monday, 07:00 AM
December Hall E1
7, 2015*

Pembrolizumab in Combination with Lenalidomide and Low-Dose Dexamethasone for Relapsed/Refractory Multiple Myeloma (RRMM): Keynote-023 -505

Jesus San Miguel, MD, PhD, Maria-Victoria Mateos, MD, PhD, Jatin J. Shah, MD, Enrique M. Ocio, MD, PhD, Paula Rodriguez-Otero, MD, PhD, Donna Reece, MD, Nikhil C. Munshi, MD, David E. Avigan, MD, Yang Ge, PhD, Arun Balakumaran, MD, PhD, SM, Patricia Marinello, PharmD, Robert Z. Orlowski, MD, PhD, David S Siegel, MD, PhD

*07:00 AM -
08:30 AM*

653. Myeloma: Therapy, excluding Transplantation: Novel Combinations in Immuno-Oncology

Nikhil C. Munshi, MD, Paul G. Richardson, MD, Paul G. Richardson, MD, Patrizia Tosi, MD, Nikhil C. Munshi, MD

07:15 AM

A Phase II Study of Anti PD-1 Antibody Pembrolizumab, Pomalidomide and Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma (RRMM) -506

Ashraf Z. Badros, MD, Mehmet H. Kocoglu, MD, Ning Ma, NP, Aaron P. Rapoport, MD, Emily Lederer, RN, Sunita Philip, MBBS, Patricia Lesho, Cameron Dell, Nancy M. Hardy, MD, Jean Yared, MD, Olga Goloubeva, PhD, Zeba Singh, MD

07:30 AM

Daratumumab in Combination with Lenalidomide and Dexamethasone in Patients with Relapsed or Relapsed and Refractory Multiple Myeloma: Updated Results of a Phase 1/2 Study (GEN503) -507

Torben Plesner, MD, Hendrik-Tobias Arkenau, Peter Gimsing, Jakub Krejcik, Charlotte Lemech, Monique C. Minnema, Ulrik Lassen, Jacob P. Laubach, MD, Antonio Palumbo, Steen Lisby, Linda Basse, Jianping Wang, A Kate Sasser, Mary E Guckert, Howard Yeh, Tahamtan Ahmadi, Henk M. Lokhorst, Paul G. Richardson, MD

07:45 AM

Open-Label, Multicenter, Phase 1b Study of Daratumumab in Combination with Pomalidomide and Dexamethasone in Patients with at Least 2 Lines of Prior Therapy and Relapsed or Relapsed and Refractory Multiple Myeloma -508

Ajai Chari, MD, Sagar Lonial, MD, Attaya Suvannasankha, Joseph W. Fay, Bertrand Arnulf, Jainulabdeen J. Ifthikharuddin, Xiang Qin, Tara Masterson, Kerri Nottage, Jordan M Schecter, Tahamtan Ahmadi, Brendan Weiss, Amrita Krishnan, Suzanne Lentzsch

08:00 AM

A Dose Finding Phase II Trial of Isatuximab (SAR650984, Anti-CD38 mAb) As a Single Agent in Relapsed/Refractory Multiple Myeloma -509

Thomas Martin, MD, Joshua Richter, MD, Ravi Vij, MD, Craig Cole, MD, Djordje Atanackovic, MD, Jeffrey Zonder, MD, Jonathan L. Kaufman, MD, William Bensinger, MD, Meletios A. Dimopoulos, Jesús San Miguel, MD PhD, Todd Zimmerman, MD, Nikoletta Lendvai, MD PhD, Parameswaran Hari, MD, MRCP, MS, Enrique M. Ocio, MD, PhD, Cristina Gasparetto, MD, Shaji Kumar, MD, Karl Hsu, MD, Eric

Charpentier, MSc, Stephen A. Strickland, MD, Joseph Mikhael, MD

08:15 AM Elotuzumab Plus Bortezomib and Dexamethasone Versus Bortezomib and Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma: 2-Year Follow-up -510
Antonio Palumbo, MD, Massimo Offidani, MD, Brigitte Pégourie, Javier De La Rubia, Laurent Garderet, MD, Kamel Laribi, Alberto Bosi, MD, Roberto Marasca, MD, Jacob P. Laubach, MD, Ann Mohrbacher, MD, Angelo Michele Carella, MD, Anil K. Singhal, Mark Lynch, Ying-Ming Jou, Andrzej Jakubowiak, MD, PhD

**04:30 PM -
06:00 PM** ASH/FDA Joint Symposium on Late-Breaking Drug Approvals
Hall D Albert B. Deisseroth, MD, PhD

FDA Approval of Daratumumab
Barry W. Miller, MSN, CRNP

FDA Approval of Ixazomib
Alexandria Schwarsin, MD

FDA Approval of Elotuzumab
Nicole J. Gormley, MD

Clinical Perspective
S. Vincent Rajkumar, MD

Clinical Perspective
Paul G. Richardson, MD

Panel Discussion
Albert B. Deisseroth, MD, PhD, Barry W. Miller, MSN, CRNP, Alexandria Schwarsin, MD, Nicole J. Gormley, MD, S. Vincent Rajkumar, MD, Paul G. Richardson, MD, Ann T. Farrell, MD, Romeo Angelo De Claro, MD

**Tuesday,
December
8, 2015** **11:30 AM -
01:00 PM** Best of ASH
Hall D Andrew W. Roberts, MBBS, PhD, Akiko Shimamura, MD, PhD